CN201 is a novel CD3xCD19-targeting T-cell-engager bispecific antibody, designed to target B cells for elimination by T cells. CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical …
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=66b60286e92e43d88918917404cfe140&url=https%3A%2F%2Fwww.eagletribune.com%2Fregion%2Fmerck-to-acquire-investigational-b-cell-depletion-therapy-cn201-from-curon-biopharmaceutical%2Farticle_a8c4214b-49a1-56d6-b2fe-dd870a4bcba7.html&c=6876735503359511612&mkt=en-us
Author :
Publish date : 2024-08-08 19:45:00
Copyright for syndicated content belongs to the linked Source.